相似文献
1
Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
Antimicrob Agents Chemother. 1999 Oct;43(10):2372-5. doi: 10.1128/AAC.43.10.2372.
2
Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin.
Infection. 2000 Jan-Feb;28(1):13-20. doi: 10.1007/s150100050004.
3
Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.
Antimicrob Agents Chemother. 1998 Apr;42(4):991-2. doi: 10.1128/AAC.42.4.991.
4
Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):119-23. doi: 10.1016/0732-8893(95)00044-b.
5
In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
Diagn Microbiol Infect Dis. 1997 Dec;29(4):233-9. doi: 10.1016/s0732-8893(97)00161-2.
6
Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae.
Chemotherapy. 2000 Sep-Oct;46(5):303-8. doi: 10.1159/000007302.
7
In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin.
Microb Drug Resist. 1996 Fall;2(3):361-9. doi: 10.1089/mdr.1996.2.361.
8
Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Diagn Microbiol Infect Dis. 1998 Oct;32(2):119-26. doi: 10.1016/s0732-8893(98)00072-8.
9
Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
J Antimicrob Chemother. 1999 Jun;43(6):811-6. doi: 10.1093/jac/43.6.811.
10
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.
Antimicrob Agents Chemother. 1998 Apr;42(4):942-4. doi: 10.1128/AAC.42.4.942.
引用本文的文献
1
Treatment of Bacterial Meningitis.
Curr Infect Dis Rep. 2002 Feb;4(1):7-16. doi: 10.1007/s11908-002-0062-7.
2
Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Dec;45(12):3328-33. doi: 10.1128/AAC.45.12.3328-3333.2001.
3
Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections.
Curr Infect Dis Rep. 2000 Oct;2(5):399-408. doi: 10.1007/s11908-000-0066-0.
本文引用的文献
1
Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin.
Antimicrob Agents Chemother. 1999 Jun;43(6):1480-3. doi: 10.1128/AAC.43.6.1480.
2
Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.
Antimicrob Agents Chemother. 1999 Apr;43(4):963-5. doi: 10.1128/AAC.43.4.963.
3
Management of infections due to antibiotic-resistant Streptococcus pneumoniae.
Clin Microbiol Rev. 1998 Oct;11(4):628-44. doi: 10.1128/CMR.11.4.628.
4
Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis.
Antimicrob Agents Chemother. 1998 Oct;42(10):2650-5. doi: 10.1128/AAC.42.10.2650.
5
High-level beta-lactam resistance in strains of Streptococcus pneumoniae isolated in the UK.
J Antimicrob Chemother. 1998 Jul;42(1):115-6. doi: 10.1093/jac/42.1.115.
6
Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.
Antimicrob Agents Chemother. 1998 Apr;42(4):991-2. doi: 10.1128/AAC.42.4.991.
7
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.
Antimicrob Agents Chemother. 1998 Apr;42(4):942-4. doi: 10.1128/AAC.42.4.942.
8
Bactericidal activity against intermediately cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with bacterial meningitis treated with high doses of cefotaxime and vancomycin.
Antimicrob Agents Chemother. 1997 Sep;41(9):2050-2. doi: 10.1128/AAC.41.9.2050.
9
In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae.
J Antimicrob Chemother. 1997 Jun;39 Suppl B:51-5. doi: 10.1093/jac/39.suppl_2.51.
10
Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.
Antimicrob Agents Chemother. 1997 Jun;41(6):1298-300. doi: 10.1128/AAC.41.6.1298.
Zotero 插件